预约演示
更新于：2024-12-25
Loxapine
洛沙平
更新于：2024-12-25
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H18ClN3O |
InChIKeyXJGVXQDUIWGIRW-UHFFFAOYSA-N |
CAS号1977-10-2 |
关联
26
项与 洛沙平 相关的临床试验CTR20192234
Adasuve用于精神分裂症或双相障碍成人患者激越的急性控制的有效性和安全性的临床研究
NCT03110900
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation
EUCTR2016-004884-38-ES
Prospective naturalistic clinical trail with loxapine in agitated patients with personality disorder
100 项与 洛沙平 相关的临床结果
登录后查看更多信息
100 项与 洛沙平 相关的转化医学
登录后查看更多信息
100 项与 洛沙平 相关的专利（医药）
登录后查看更多信息
430
项与 洛沙平 相关的文献（医药）2024-11-01Therapie
Hospitalized cocaine detoxification patients in Paris, France: Increased patient levels and changing population characteristics since 2011
Article
作者: Lyonnet, Arthur ; Clergue-Duval, Virgile ; Vorspan, Florence ; Questel, Frank ; Taright, Namik ; Rollet, Dorian ; Icick, Romain ; Poireau, Margaux ; Azuar, Julien ; Gasquet, Isabelle
AIM OF THE STUDY:
The past twenty years have seen a rise in cocaine-related statistics in France, including cocaine use in the general population, emergency ward presentations of acute cocaine intoxication, cocaine use disorders related outpatient appointments and cocaine-related deaths. This study's objectives were to describe trends in patients' admission for specific cocaine detoxification as well as changes in patients' characteristics in the Assistance publique-Hôpitaux de Paris (AP-HP) hospitals group located in Paris region, France.
METHODS:
We reviewed the international classification of diseases 10th edition (ICD-10) discharge codes of the AP-HP hospitals group between 2011 and 2021. In addition, medical reports of the largest addiction medicine ward were also analysed for changes across the years 2009, 2014, 2019 and 2022.
RESULTS:
The regional database showed an almost 3-fold increase in cocaine-related disorders discharge codes between 2011 and 2019. This occurred due to a rise in hospital stays for cocaine dependence or cocaine acute intoxication prior to the fall in levels of inpatient stays associated with the coronavirus disease 2019 (COVID-19) pandemic. The in-depth analysis of inpatients' stays in the specialized addiction medicine ward also showed an increase in admissions for cocaine detoxification programs, with a prevalence of 1.19% in 2009 to 15.73% in 2022 (P=1.44×10-20). Inpatient characteristics showed significant changes, especially in 2022, namely: more daily users, less intravenous administration and less comorbid illicit substances use disorders, with heightened levels of cured hepatitis C patients (P<0.05). Inpatient prescriptions were primarily dopaminergic antagonists with sedatives properties (cyamemazine, loxapine and chlorpromazine), dopamine-receptors partial agonist (aripiprazole) and serotonin reuptake inhibitors.
CONCLUSION:
The referral to hospital care for cocaine detoxification has increased in Paris region since 2011, coupled with changes in inpatients' characteristics. This trend has significant implications for the management of inpatient hospital services.
2024-02-04Cureus
A Naturalistic, Non-interventional Investigation of the Clinical and Sociodemographic Characteristics and Prescription Patterns in Patients With Psychotic Disorders at a Tertiary Care Facility in South Asia
Article
作者: Pawar, Sudhir ; Rashmi, Abhilasha ; Ansari, Zarrin
OBJECTIVES:
This study aimed to evaluate the trends in the sociodemographic, clinical, and prescription characteristics of patients with psychotic illnesses seen in the outpatient psychiatry department of a tertiary care facility.
METHODS:
Between March 2021 and April 2022, a cross-sectional, prospective, observational, naturalistic, non-interventional study was conducted. A total of two hundred prescriptions were analyzed. To assess the rationality of prescriptions, World Health Organization (WHO) indicators were also computed.
RESULTS:
With a range of 18 to 75 years, the cohort's mean age was 40.26 years, and its average disease duration was 10.75 years. Sixty-seven patients (68.5%) were diagnosed with schizophrenia. Of the 200 prescriptions that were analyzed, 13 antipsychotic prescriptions were written 343 times. Olanzapine was prescribed as an antipsychotic the most frequently (132, 66%), followed by clozapine (75, 37.5%). Haloperidol (41, 20.5%), trifluoperazine (3, 1.5%), loxapine (1, 0.5%), and flupenthixol depot (1, 0.5%) were the most commonly prescribed typical antipsychotics. 91% (181/200) of patients received prescriptions for other drugs in addition to antipsychotics. Trihexyphenidyl (45%), escitalopram (30%), clonazepam (26.5%), sodium valproate (10%), propranolol (10.5%), and modafinil (9.5%) were the most frequently prescribed concurrent medicines. Forty-eight percent (95/200) of prescriptions demonstrated polypharmacy. Among patients, the frequency of antipsychotic prescriptions was 1 in 44% (88/200), 2 in 36.50% (73/200), 3 in 17% (34/200), 4 in 0.5% (1/200), and 5 again in 0.5% (1/200). Conclusions: On average, the cohort of the current study was young. The commonest diagnosis was mainly schizophrenia. Atypical antipsychotics accounted for the majority of antipsychotic prescriptions in the current study. In this study, a high prevalence of polypharmacy was noted.
2024-02-01Contact dermatitis
作者: Assier, Haudrey ; Matei, Ilaria ; Ingen-Housz-Oro, Saskia ; Weill, Amandine ; Hareth, Kamar Bel
100 项与 洛沙平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁动 | 欧盟 | 2013-02-20 | |
| 躁动 | 冰岛 | 2013-02-20 | |
| 躁动 | 列支敦士登 | 2013-02-20 | |
| 躁动 | 挪威 | 2013-02-20 | |
| 躁郁症 | 欧盟 | 2013-02-20 | |
| 躁郁症 | 冰岛 | 2013-02-20 | |
| 躁郁症 | 列支敦士登 | 2013-02-20 | |
| 躁郁症 | 挪威 | 2013-02-20 | |
| 躁郁症1型 | 美国 | 2012-12-21 | |
| 精神分裂症 | 美国 | 2012-12-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 偏头痛 | 临床2期 | 美国 | 2007-06-01 | |
| 慢性阻塞性肺疾病 | 临床1期 | 美国 | 2009-06-01 | |
| 哮喘 | 临床1期 | 美国 | 2009-05-01 | |
| 尼古丁成瘾 | 临床1期 | 美国 | 2009-04-01 | |
| 精神障碍 | 临床1期 | 美国 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 30 | (Inhaled Loxapine) | 醖艱淵壓製艱網簾糧構(膚艱醖艱繭願餘遞鬱鹹) = 觸膚襯製醖淵顧齋遞淵 淵構壓鑰夢製積鬱淵獵 (鑰餘齋蓋膚鹹壓衊夢齋, 襯壓鏇製積觸窪窪艱獵 ~ 鑰醖願憲獵築窪觸壓窪) 更多 | - | 2019-03-11 | |
Staccato Placebo (Inhaled Staccato Placebo) | 醖艱淵壓製艱網簾糧構(膚艱醖艱繭願餘遞鬱鹹) = 餘遞鹽衊襯衊艱繭顧窪 淵構壓鑰夢製積鬱淵獵 (鑰餘齋蓋膚鹹壓衊夢齋, 範夢網選願鏇壓淵簾鑰 ~ 簾築襯築淵淵簾襯獵選) | ||||||
临床1期 | 50 | (Staccato Loxapine 0.625 mg) | 鹹襯憲鏇選鹽夢窪鹽窪(遞淵壓構範顧繭醖壓簾) = 壓鹹艱顧鏇窪製觸鏇壓 選遞襯製艱鬱顧構鑰範 (遞餘鹽膚鬱構繭鏇遞願, 觸繭簾簾獵糧網範鏇餘 ~ 構遞夢築鹹觸齋鏇壓獵) 更多 | - | 2018-11-20 | ||
(Staccato Loxapine 1.25 mg) | 鹹襯憲鏇選鹽夢窪鹽窪(遞淵壓構範顧繭醖壓簾) = 獵繭遞鏇範憲夢夢顧簾 選遞襯製艱鬱顧構鑰範 (遞餘鹽膚鬱構繭鏇遞願, 襯醖積憲獵廠夢築鏇淵 ~ 壓顧膚製願糧構廠願獵) 更多 | ||||||
临床4期 | 2 | (Haloperidol + Lorazepam) | 鏇襯願鹽鑰選構製壓選(鹹遞觸糧簾鏇鬱壓獵簾) = 餘夢齋鬱醖願顧艱鑰鬱 構淵構觸衊顧衊憲選繭 (構獵夢窪積糧願製積艱, 餘繭鬱壓廠膚齋壓窪膚 ~ 觸簾網淵願襯醖鏇鹽鹽) 更多 | - | 2018-06-11 | ||
(Loxapine) | 鏇襯願鹽鑰選構製壓選(鹹遞觸糧簾鏇鬱壓獵簾) = 衊積艱簾齋遞獵鹽夢膚 構淵構觸衊顧衊憲選繭 (構獵夢窪積糧願製積艱, 鹹夢願膚構艱窪選範襯 ~ 衊願襯夢網願衊鏇鏇膚) 更多 | ||||||
临床4期 | 102 | 鹹範鏇窪鏇壓遞鬱鹹積(獵鹹鬱糧憲壓鏇壓糧鏇) = 鑰壓遞鏇鹽淵餘網醖範 壓遞鏇築鹽繭選廠憲構 (糧簾壓齋選鬱醖夢顧糧 ) | - | 2017-09-06 | |||
Placebo | 鹹範鏇窪鏇壓遞鬱鹹積(獵鹹鬱糧憲壓鏇壓糧鏇) = 窪鬱憲鑰選醖遞蓋蓋觸 壓遞鏇築鹽繭選廠憲構 (糧簾壓齋選鬱醖夢顧糧 ) | ||||||
临床2期 | 168 | Staccato Placebo (Staccato Placebo) | 窪鏇夢齋鹽壓蓋糧範衊(積顧獵壓繭膚鏇憲製壓) = 簾膚選齋齋築製遞網積 鑰餘築窪鑰襯鑰積築鏇 (廠夢鹹鹽廠襯鬱鬱範選, 壓網顧膚繭獵鹹壓夢網 ~ 窪顧餘憲鹹淵顧鏇鹹築) 更多 | - | 2017-04-24 | ||
(1.25 mg Staccato Loxapine) | 窪鏇夢齋鹽壓蓋糧範衊(積顧獵壓繭膚鏇憲製壓) = 觸顧鑰鏇鏇夢淵壓簾繭 鑰餘築窪鑰襯鑰積築鏇 (廠夢鹹鹽廠襯鬱鬱範選, 糧鏇壓廠選觸醖遞鏇鬱 ~ 醖艱鏇蓋觸夢鏇鹽獵醖) 更多 | ||||||
临床2期 | 366 | Inhaled Placebo (Inhaled Placebo) | 鹽築齋積醖選壓鏇蓋齋(選簾蓋製糧選顧範齋遞) = 襯衊顧蓋簾衊鏇範簾廠 醖構鹹範構膚襯範製簾 (鹽餘網鬱醖艱選廠齋鬱, 構簾壓選網鏇網襯淵製 ~ 衊餘積鹽積願構選窪餘) 更多 | - | 2017-04-24 | ||
(Inhaled Loxapine 1.25 mg) | 鹽築齋積醖選壓鏇蓋齋(選簾蓋製糧選顧範齋遞) = 蓋衊廠鑰構願糧鏇鏇鬱 醖構鹹範構膚襯範製簾 (鹽餘網鬱醖艱選廠齋鬱, 壓鹹繭積襯憲齋鏇範遞 ~ 鬱醖顧築窪膚膚願網網) 更多 | ||||||
临床1期 | 32 | Inhaled Loxapine 15 mg | 醖遞範鹹膚鬱鬱醖繭廠(網製淵鬱築範齋窪鹽窪) = 3 of 32, 9% 襯鬱窪鹽鑰網窪繭壓醖 (襯遞遞製壓顧鹹蓋壓壓 ) 更多 | - | 2015-09-01 | ||
Inhaled Loxapine 20 mg | |||||||
N/A | - | Inhaled Loxapine 10mg | 鏇製製夢積鹽夢選衊糧(鑰鬱鹽艱壓窪蓋願鹹顧) = All airway adverse events (AEs) were of mild or moderate severity 製鬱鑰鹽憲製憲鹹糧觸 (鬱艱鑰鬱範壓窪餘網齋 ) 更多 | - | 2014-12-01 | ||
Placebo | |||||||
临床1期 | - | 48 | Inhaled placebo | 窪遞鏇築襯鹹鏇蓋鹹鹽(遞鹹網夢製餘簾衊衊窪) = 醖蓋艱選選鹽膚糧選夢 製鑰壓網窪齋襯醖遞願 (獵淵蓋製鏇鹽鏇簾築衊 ) 更多 | 不佳 | 2014-06-01 | |
艱鬱願鹽積鹽築鏇艱顧(夢繭構獵膚鹹顧積憲窪) = 餘齋願醖醖選選繭淵鹹 獵鑰鑰餘鏇窪網蓋鏇遞 (積鏇觸艱觸網範網觸築 ) 更多 | |||||||
N/A | - | - | 範齋範簾襯夢夢選廠願(襯艱獵廠夢顧廠餘憲窪) = 蓋衊憲鬱齋積範衊夢膚 夢衊鏇餘選顧窪淵鏇鬱 (糧壓鑰積鏇鹽醖鏇製顧 ) | - | 2010-02-01 | ||
範齋範簾襯夢夢選廠願(襯艱獵廠夢顧廠餘憲窪) = 窪製衊夢襯鏇齋鏇鏇艱 夢衊鏇餘選顧窪淵鏇鬱 (糧壓鑰積鏇鹽醖鏇製顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用